Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.30 |
| ▸ | TRPC7 | Q9HCX4 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PTGES | O14684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26782493 | 1.00 | CETP (0.33) | CETPNR1H2NR1H3GPBAR1GRM2 | |
| SCHEMBL25320077 | 0.90 | TIPARP (0.32) | — | |
| SCHEMBL25901613 | 0.84 | HTR2C (0.34) | FAAHTRPC3TRPC7NPSR1 | |
| SCHEMBL31058376 | 0.84 | HTR2C (0.34) | FAAHTRPC3TRPC7NPSR1 | |
| SCHEMBL30550891 | 0.76 | HTR1A (0.33) | GRM2 | |
| SCHEMBL25320710 | 0.76 | HTR1A (0.33) | GRM2 | |
| SCHEMBL26782492 | 0.75 | TNF (0.34) | TRPC3TRPC7NPSR1 | |
| SCHEMBL31058380 | 0.75 | TNF (0.34) | TRPC3TRPC7NPSR1 | |
| SCHEMBL25321271 | 0.73 | TIPARP (0.33) | — | |
| SCHEMBL25898093 | 0.72 | LMNA (0.41) | GRM2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459922-B2 | PARP7 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4469448-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-12-04 | — | — | EP | disclosed |
| CN-118591537-A | PARP7 inhibitors | 吉利德科学公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023147418-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459922-B2 | PARP7 inhibitors | PARP1, PARP11, PARP2 | CETP 3533/4885NR1H2 2769/4885NR1H3 2249/4885 |
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | CETP 3533/4885NR1H2 2769/4885NR1H3 2249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.